ArticleJournal of thoracic disease2025
SYVN1 aggravates esophageal squamous cell carcinoma development by activating NF-κB pathway to facilitate macrophage M2 polarization.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a leading lethal cancer in the digestive system. Tumor-associated macrophages (TAMs) are key participators in ESCC progression. Mounting evidence has testified the regulatory function of synoviolin (SYVN1) in cancer development. However, the correlation between SYVN1 and TAM polarization remains unclear. As a result, the goal of the present study was to shed light on the new mechanism of SYVN1 in ESCC. Methods: Collect clinical samples and culture ESCC cell lines to detect SYVN1 expression in ESCC. Construct small interfering RNA targeting SYVN1 and transfect it into ESCC cells to observe its effects on malignant biological processes in cancer cells and macrophage polarization. Use a co-culture system to observe the effects of si-SYVN1 and macrophage polarization on pyroptosis levels in ESCC cells. In addition, we explored the relationship between SYVN1 and pivotal modulatory factors of nuclear factor kappa B (NF-κB) signaling pathway. In plus, we used a xenograft model to observe the effect of si-SYVN1 on subcutaneous tumor growth. Results: It was found that SYVN1 was upregulated at messenger RNA (mRNA) and protein levels in tissue samples and cells of ESCC. Knocking down of SYVN1 attenuated the malignant behaviors of ESCC cells Conclusions: Overall, this study illustrated that SYVN1 promoted the M2 polarization of TAMs to induce ESCC progression by targeting DDX5 and eEF1A2 to activate NF-κB pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.